Activation of the sonic hedgehog signaling controls human pulmonary arterial smooth muscle cell proliferation in response to hypoxia  by Wang, Guansong et al.
Biochimica et Biophysica Acta 1803 (2010) 1359–1367
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrActivation of the sonic hedgehog signaling controls human pulmonary arterial
smooth muscle cell proliferation in response to hypoxia
Guansong Wang a,b,1, Zhiyuan Zhang a,c,1, Zhi Xu a, Hongjin Yin a, Li Bai a, Zhuang Ma c, Mark A. DeCoster d,
Guisheng Qian a,⁎, Guangyu Wu b,⁎
a Institute of Respiratory Diseases, Xinqiao Hospital of the Third Military Medical University, Chongqing 400037, P.R. China
b Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
c Department of Respiratory Diseases, General Hospital of Shenyang, Shenyan 110016, P.R. China
d Biomedical Engineering and Institute for Micromanufacturing, Louisiana Tech University, Ruston, LA 71272, USA⁎ Corresponding authors. G. Wu is to be contacted at
and Experimental Therapeutics, Louisiana State Universi
Orleans, Louisiana 70112, USA. Tel.: +1 504 568 2236;
Institute of Respiratory Diseases, Xinqiao Hospital o
University, Chongqing 400037, P.R. China. Tel.: +86 23
1653.
E-mail addresses: qiangs@mail.tmmu.com.cn (G. Qia
1 These authors contributed equally to this work.
0167-4889/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbamcr.2010.09.002a b s t r a c ta r t i c l e i n f oArticle history:
Received 14 March 2010
Received in revised form 27 August 2010
Accepted 1 September 2010
Available online 15 September 2010
Keywords:
Anoxia
Hedgehog signal pathway
Sonic hedgehog
GLI
Cell proliferation
Human pulmonary arterial smooth
muscle cellsThe hedgehog signal pathway plays a crucial role in the angiogenesis and vascular remodeling. However, the
function of this pathway in the pulmonary vascular smooth cell proliferation in response to hypoxia remains
unknown. In this study, we have demonstrated that the main components of the hedgehog pathway,
including sonic hedgehog (SHH), patched1 (PTCH1), smoothened (SMO), GLI and hypoxia-inducible factor 1
(HIF1) are expressed in the human pulmonary arterial smooth muscle cells (HPASMCs). Interestingly,
hypoxia signiﬁcantly enhanced the expression of SHH and HIF1, facilitated the translocation of GLI1 into the
nuclei, and promoted the proliferation of HPASMCs. Furthermore, direct activation of the SHH pathway
through incubation with the puriﬁed recombinant human SHH or with purmorphamine and SAG, two Smo
agonists, also enhanced the proliferation of HPASMCs. Importantly, the treatment with anti-SHH and anti-
HIF1 antibodies or cyclopamine, a speciﬁc SMO inhibitor, markedly inhibited the nuclear translocation of GLI1
and cell proliferation in the HPASMCs induced by hypoxia and activation of the SHH pathway. Moreover, the
treatment with cyclopamine increased apoptosis in the hypoxic HPASMCs. These data strongly demonstrate
for the ﬁrst time that the SHH signaling plays a crucial role in the regulation of HPASMC growth in response to
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It has been well documented that hypoxia enhances the progress
of vascular remodeling in a number of human diseases, including
atherosclerosis, pulmonary artery hypertension and chronic obstruc-
tive pulmonary disease [1–4]. During vascular remodeling, vascular
smooth muscle cells (VSMCs) undergo proliferation, hypertrophy,
migration, and/or apoptosis [5–9]. The molecular mechanisms
responsible for these alterations under the hypoxic condition have
been extensively studied and indeed, a number of signaling pathways,
such as the JAKs/STATs [10,11], PI3 kinase/Akt [12,13], and mitogen-
activated protein kinase pathways [14,15], have been demonstrated
to play important roles in the regulation of VSMC phenotypes.Hedgehog (HH) proteins are secreted glycoproteins that bind to the
plasmamembrane receptor Patched (PTCH) [16–20]. PTCH1 is a twelve-
transmembrane receptor that negatively regulates the function of
Smoothened (SMO). SMO possess a seven-transmembrane domain, a
characteristic of the superfamily of G protein-coupled receptors, and
recent studies have demonstrated that the function of SMO may be
indeedmediated through coupling to heterotrimeric G proteins [21,22].
Under the normal condition, the function of SMO is suppressed by
PTCH1. Upon HH binding to PTCH1, the inhibitory effect of PTCH1 on
SMO will be released resulting in the activation of SMO and the GLI
family of transcriptional factors, initiating expression of target genes
including those associated with cell cycle progression [23–25]. Three
members of the hedgehog family, Sonic hedgehog (SHH), Indian
hedgehog, and Desert hedgehog and three GLI proteins, GLI1, GLI2
and GLI3 have been identiﬁed. The SHH signaling pathway was ﬁrst
discovered to control the segmentation patter of Dorsophila and has
been shown to regulate cell migration, proliferation, and apoptosis in
several cell lines, such as cancer cells, neuron cells, and aortic VSMCs
[9,26–33]. Particularly, the activation of the SHH signaling pathway is
associated with retinal neovascularization, neural progenitor prolifer-
ation and muscle regeneration under the hypoxic condition [34–36]. It
has also been demonstrated that nuclear translocation of GLI1 induces
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all are involved in the regulation of cell proliferation [37–39].
Hypoxia has been demonstrated to activate the SHH pathway in
cardiomyoblast cells, neurons, astrocytes, and neural progenitor cells
[35,40–43]. Hypoxia has also been demonstrated to induce the
expression of SHH which is dependent on hypoxia-inducible factor-
1 (HIF1), a transcription factor that modulates a variety of gene
expression [40,42,44,45]. However, the function of the SHH signaling
pathway in the human pulmonary arterial smooth muscle cells
(HPASMCs) has not been studied under the normal and hypoxia
conditions. In the present study, we have demonstrated that hypoxia
markedly activates the SHH signaling pathway in the adult HPASMCs
which contributes to the enhanced cell proliferation of the HPASMCs.
2. Materials and methods
2.1. Materials
Antibodies against Shh (C9C5, #2207) were purchased from Cell
Signaling Technology (Danvers, MA). Antibodies against and GAPDH
(0411, sc-47724), PTCH1 (sc-9016), GLI1 (H-300, sc-20687) and HIF1α
(H-206, sc-10790) and thyl-N′-(3-pyridinylbenzyl)-N′-(3-chlorobenzo
[b]thiophene-2-carbonyl)-1,4-diaminocyclohexane (SAG) were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Antibodies against TATA binding protein (TBP) was from Abcam
([1TBP18], #ab818, Cambridge, MA). Recombinant human SHH amino
terminal peptide was from R&D Systems (Abingdon, UK). Cyclopamine
(CyA) was from Biomol International (Biomol Research Laboratories,
Plymouth Meeting, PA). SuperSignal West Pico Chemiluminescent
Substrate Kits (Horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG luminal/enhancer solution stable peroxide solution) were
fromThermo Fisher Scientiﬁc (Rockford, IL). Secondary antibodieswere
from Amersham Biosciences (Little Chalfont, UK). Apoptosis Assay Kit
was from Molecular Probes (Invitrogen, Eugene, OR). The SYBR
PrimeScript RT-PCR kit was from TaKaRa Biotechnology (Dalian,
China). All other materials were described elsewhere [46].
2.2. Cell culture
The HPASMCs were purchased from ScienCell Research Laborato-
ries (Carlsbad, CA, USA) and cultured in smooth muscle cell medium
(SMCM) supplemented with 2% fetal bovine serum (FBS), 100 U/ml
penicillin, 100 μg/ml streptomycin, and 1% smoothmuscle cell growth
supplement (SMCGS, No. 2415 from ScienCell Research Laboratories,
Carlsbad, CA, USA). The ﬁnal concentrations of SMCGS components are
bovine serum albumin (BSA) 10 μg/ml, apo-transferrin 10 μg/ml,
insulin 5 μg/ml, FGF-2 2 ng/ml, IGF-I 2 ng/ml and hydrocortisone
1 μg/ml. TheHPASMCswere used at passages 4-10 in our experiments.
2.3. HPASMC exposure to hypoxia and pretreatments
Hypoxic culture conditions deﬁned as 3% O2 were created in an
oxygen-regulated cell culture incubator (Heraeus, Germany). Sub-
conﬂuent HPASMCs were starved in SMCM with 0.4% FBS for at least
24 h and then incubated under either hypoxic or normoxic conditions
for various periods of time.
For the pretreatment of the HPASMCs, the cells were preincubated
with CyA (5 μM for 2 h), tomatidine (Tom) (5 μM for 2 h), SHH
(1.0 μg/ml for 24 h), purmorphamine (Pur) (4 μΜ for 24 h), SAG
(100 nM for 24 h), anti-SHH antibodies (1 μg/ml for 24 h) or anti-
HIF1 antibodies (1 μg/ml for 24 h) and then subjected to hypoxia.
2.4. Measurement of SHH in the culture medium of hypoxic HPASMCs
The concentrations of SHH in the culture medium of hypoxic
HPASMCs were measured by using an ELISA kit according to themanufacturer's instructions (R&D Systems) and the cells were cultured
on 96-well, ﬂat bottom, and EIA/RIA plates (Corning, NY, USA). A
standard curve was generated for each experiment using known
concentrations of SHH from 0 to 10,000 pg/ml. The concentration of
SHH in the conditioned media fell with the linear range of the standard
curve and thus, the SHHconcentration in themediawas calculated from
the standard curve by interpolation.
2.5. Quantitative real-time RT-PCR
Total RNAs were extracted from the HPASMCs using TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer's instruction.
Six μg of total RNAs were used for cDNA synthesis with the SuperScript
ﬁrst-strand synthesis system for RT-PCR (Invitrogen). Quantitative real-
time RT-PCR was carried out using the Rotor Gene (model RG-6000;
Corbett Research, Sydney, Australia) and the SYBR green PCR kit. The
primers used were: For SHH, forward primer: 5′-TCCAGAAACTCCGAGC-
GATTTAAG-3′ and reverse primer: 5′-CACTTCCTGGCCACTGGTTCA-3′;
For PTCH1, forward primer: 5′-CCACAGAAGCGCTCCTACA-3′ and reverse
primer: 5′-CTGTAATTTCGCCCCTTCC-3′; For Smoothened (SMO), for-
ward primer: 5′-ACGAGGACGTGGAGGGCTG-3′ and reverse primer: 5′-
CGCACGGTATCGGTAGTTCT-3′; For GLI1, forward primer: 5-GGGAT
GATCCCACATCCTCAGTC-3 and reverse primer: 5-CTGGAGCAGCCCCCC-
CAGT-3; For GLI2, forward primer: 5'-ACACGGGCTTTGGTCTCA-3' and
reverse primer: 5'-CCCTTGGGCATAGCTTCT-3'. For GLI3, forward primer:
5'-ACCATGGGCTTCAGTCAG-3' and reverse primer: 5'-CAATCTG-
CACGCCTTCTA-3'; For GAPDH, forward primer: 5'-AACGACCCCTTCATT-
GAC-3' and reverse primer: 5'-TCCACGACATACTCAGCAC-3'. The
following program was used: denaturation at 95 °C for 5 min and 40
cycles consistingofdenaturationat95 °C for10 sec, annealingat 56-65 °C
for 5 sec, andextension at 72 °C for 13 sec. The speciﬁcity of the ampliﬁed
PCR products was assessed by a melting curve analysis. The crossing-
point value (Cp), which is inversely proportional to the initial template
copy number, was determined by the Light Cycler Software Program
provided by the manufacturer.
2.6. Immunoﬂuorescence microscopy
Immunoﬂuorescence microscopy was performed as described
previously [47,48]. HPASMCs were seeded onto 96-well plates at a
density of 2×103 cells per well. After washingwith PBS, the cells were
ﬁxed with 2% formaldehyde for 15 min at room temperature,
permeabilized in methanol (-20 °C, 10 min), and blocked in 1% BSA
for 60 min. The cells were then incubated with anti-GLI1 antibodies at
1:100 dilution at 4 °C overnight. Following three times washes with
PBS, the cells were incubated with secondary antibodies (1:200
dilution) for 1 h at 37 °C. The cells were then washed three times
(5 min each) in PBS before visualization with the use of a ﬂuorescent
microscope (Olympus IX-71) using appropriate excitation and
emission spectra at ×200 magniﬁcation.
2.7. Protein extraction and Western blotting analysis
The HPASMCs were made quiescent by serum starvation for 24 h
and then exposed to hypoxia for the different time periods [49,50].
The cells were washed with cold PBS and lysed in buffer containing
15 mM KCl, 10 mM HEPES, pH 7.6, 2 mM MgCl2, 0.1 mM EDTA, 1 mM
DTT, 0.1% Nonidet P-40, 0.5 mM PMSF, 2.5 μg/ml leupeptin, 5 μg/ml
antipain and 5 μg/ml aprotinin for 10 min on ice. After centrifugation
at 14,000×g for 20 sec at 4 °C, proteins in the nuclei were extracted by
incubation at 4 °C with vigorous vortex in buffer A containing 420 mM
NaCl, 20 mM HEPES, pH 7.9, 0.2 mM EDTA, 25% glycerol, 1 mM DTT,
0.5 mM PMSF, 2.5 μg/ml leupeptin, 5 μg/ml antipain, and 5 μg/ml
aprotinin followed by centrifugation at 13,000×g for 30 min at 4 °C.
The supernatant extract was collected and stored at −80 °C.
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Fig. 1. mRNA expression of SHH, PTCH1, SMO, GLI1, GLI2 and GLI3 in the HPASMCs as
determined by RT-PCR. The expression of GAPDH is used a positive control. Similar
results are obtained in at least three separate experiments. Molecular mass (bp) is
indicated at the left.
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PVDF membranes as described previously [51,52]. Expression of SHH,
PTCH1, GLI1, HIF1α, GAPDH and TATA binding protein (TBP) was
determined by immunoblotting using their respective antibodies at
dilution of 1:1000, 1:400, 1:600, 1:800, 1:800 and 1:2000 dilution,
respectively. Immunoreactive bandswere visualizedwith horseradish
peroxidase-conjugated secondary antibodies (1:10,000 dilution). The
peroxidase reaction was developed with an enhanced chemilumines-
cence detection system to visualize the secondary antibodies.
2.8. [3H]-Thymidine incorporation
The HPASMCs were suspended in SMCM containing 2% FBS and 1%
SMCGS, seeded in 48-well plates (105 cells per well), grown until 80% to
90% conﬂuent, and brought to quiescence by incubation with SMCM
containing 0.4% FBS for 24 h. The cells were then treated with hypoxia,
SHH, Pur, SAG and cytopamine. For [3H]-thymidine incorporation, 18 h
before termination of the cultures, cellswerepulsedwith0.5 μCi/well of
[3H]-thymidine. After the incubation period, themediumwas removed,
and the cell monolayer was washed with ice-cold PBS and then
detached by incubation with 1 ml of 0.25% trypsin for 5 min. Further
tryptic activity was inhibited by addition of 1 ml of DMEM containing
10% FCS. For the measurement of [3H]-thymidine incorporation under
the normoxia condition in response to growth factors, the cells were
treated for 24 h with 1% smooth muscle cell growth supplement
(SMCGS) with or without CyA and Tom. Total DNA containing
incorporated [3H]-thymidine was precipitated in cold 7.5% trichloroa-
cetic acid, centrifuged, washed three times with 7.5% trichloroacetic
acid, and then counted on an LKB Rackbeta scintillation counter. These
experiments were performed for 6 times each in duplicates.
2.9. Apoptosis analysis
Apoptosis was measured by using the Annexin V-propidium iodide
binding assay, followed by ﬂuorescence-activated cell sorter (FACS)
analysis using a FACScan ﬂow cytometer (Becton Dickinson, Dublin,
Ireland). TheHPASMCswere designated as viable, apoptotic, or necrotic.
The rate of apoptotic cells was detected by the Apoptosis Assay Kit
according to the manufacturer's protocol. Brieﬂy, after the cells were
harvested, washed in cold PBS and resuspended in annexin-binding
buffer, 5 μl FITC-annexin V and 10 μl propidium iodideworking solution
were added into 195 μl cell suspension. The cells were then incubated
for 10 min at room temperature. After the incubation period, 190 μl
annexin-binding buffer were added to each sample, gently mixed and
kept on ice. The stained cells were analyzed by ﬂow cytometry.
Approximately 20,000 counts were made for each sample.
2.10. Statistical analysis
Data are expressed as the means±SE. Differences were evaluated
using One-way ANOVA test, and Pb0.05 was considered as statisti-
cally signiﬁcant for all comparisons.
3. Results
3.1. Expression of components of the SHH signaling pathway in the
HPASMCs
To determine whether the major components of the SHH signaling
pathway, including SHH, PTCH1, SMO, GLI1, GLI2 and GLI3, are
expressed in the static HPASMCs, we measured their mRNA
expression levels by PCR using GADPH as a control. The mRNA of
SHH, PTCH1, SMO, GLI1, GLI2, GLI3 and GAPDH was detected in the
HPASMCs (Fig. 1) and the sizes of the PCR products matched with
their anticipated sizes of 162, 215, 258, 344, 152, 158 and 450 bp,
respectively. These data demonstrate that the SHH signaling compo-nents SHH, PTCH1, SMO, GLI1, GLI2 and GLI3 are present in the
HPASMCs.
3.2. Hypoxia induces upregulation and secretion of SHH in the HPASMCs
To explore the potential function of the SHH signaling pathway in
the HPASMCs, we determined if this pathway could be activated by
hypoxia. The expression of SHH in the HPASMCs subjected to hypoxia
was quantiﬁed by immunoblotting. The expression of SHH normalized
to GAPDHwas increased 2.2-fold at 4 h hypoxia as compared with the
normoxia group (Pb0.05). At 8 h after hypoxia, the protein level of
SHH further increased by 1.6-fold as compared with the hypoxic 4 h
group (Pb0.05). At 12 h after hypoxia, the expression of SHH was less
than the 8 h group, but still higher than the normoxia group (Pb0.05)
(Fig. 2A). In contrast, expression of PTCH1 only slightly increased and
decreased at 8 and 12 h after hypoxia, respectively (Fig. 2A.)
As SHH is a secreted glycoprotein, we then measured the
expression of SHH in the HPASMC culture medium by ELISA. The
expression of SHH in the culturemediumwas alsomarkedly increased
by hypoxia (Fig. 2B). Interestingly, the time courses of augmentation
in SHH expression and secretion into the culture medium in response
to hypoxia were different. Particularly, the expression of SHH in the
cells went down at 12 h after hypoxia, whereas SHH secretion into the
culture medium reached the highest point at 24 h after hypoxia and
remained at the same level at the 48 h hypoxia (Fig. 2B). These data
demonstrate that the expression of SHH in the HPASMCs and its
secretion into the culture medium are inducible by hypoxia.
To further determine the mechanism of the enhanced expression
of SHH protein, the mRNA level of SHH in the HPASMCs after hypoxia
was quantiﬁed by real-time PCR. ThemRNA expression level of SHH in
the HPASMCs was clearly increased in response to hypoxia and the
time course of the mRNA expression was very similar to that of the
cellular SHH protein expression. The mRNA expression of SHH was
increased by 2.5-fold at 4 h after hypoxia compared with the
normoxia group (Pb0.05). At 8 h after hypoxia, the mRNA level of
SHH further increased. At 12 h after hypoxia, the mRNA level of SHH
was reduced as compared with the 8 h group, but still higher than the
normoxia group (Pb0.05) (Fig. 2C). These data demonstrate that
hypoxia-mediated upregulation of SHH is likely mediated through
regulating the mRNA expression of SHH.
3.3. Hypoxia induces upregulation of HIF1 and its role in the expression
of SHH in the HPASMCs
It has also been demonstrated that expression of SHH in response
to hypoxia can be inhibited by blocking the function of HIF1α [40,42].
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hypoxia could also induce expression of HIF1. Similar to the SHH
expression, HIF1 expression was also markedly increased in response
to hypoxia (Fig. 3A). These data suggest that the expression of HIF1 isFig. 4. Nuclear translocation of GLI1 in the HPASMCs after hypoxia and its inhibition by p
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expression of SHH in the hypoxic HPASMCs. The pretreatment with
anti-HIF1α antibodies remarkably inhibited the enhancement of SHH
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demonstrate that hypoxia-induced SHH expression is dependent on
the normal function of HIF1α in the HPASMCs which is consistent
with an essential role of HIF1 in the expression of SHH in other cell
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incorporation as described in the “Experimental procedures”. The values are presented
as the means±S.E. of four independent experiments. * and ** Pb0.05 versus controls in
the normoxia and hypoxia groups, respectively.
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Wenext investigated if hypoxia could induce nuclear translocation
of GLI1 in the HPASMCs by two complementary methods, nuclear
fractionation followed by immunoblotting and direct visualization of
the subcellular distribution of GLI1 by immunoﬂuorescence micros-
copy. GLI1 expression was markedly increased in the nuclear fraction,
but decreased in the cytosolic fraction in the hypoxic HPASMCs as
compared with the normoxia group as measured by immunoblotting
(Fig. 4A). Consistently, microcopy analysis showed that GLI1 was
mainly expressed in the cytoplasm in the normoxia HPASMCs and
hypoxia dramatically augmented the expression of GLI1 in the nuclear
region (Fig. 4B and C). These data suggest that hypoxia induces the
nuclear translocation of GLI1.
To further prove that the facilitated nuclear translocation of GLI1 in
the HPASMCs in response to hypoxia was indeed induced by the
activation of the SHH pathway, we investigated the effect of the
treatments with anti-SHH and anti-HIF1 antibodies and CyA, a SMO
inhibitor, on theGLI1nuclear expression. TheHPASMCswerepretreated
withCyAor theantibodies and then subjected tohypoxia. The treatment
with CyA and either antibody markedly suppressed the expression of
GLI1 in the nuclear fraction measured by immunoblotting (Fig. 4A) and
nuclear translocation ofGLI1 visualized bymicroscopy (Fig. 4B andC). In
contrast, these treatments did not have clear inﬂuence on the nuclear
translocationofGLI1 in thenormoxiaHPASMCs (data not shown). These
data demonstrate that GLI1 translocation to the nuclear region in the
hypoxic HPASMCs is likely associated with the activation of the SHH
signaling pathway.
3.5. Hypoxia-induced cell proliferation and the role of the SHH pathway
It has beenwell demonstrated that hypoxia induces cell proliferation
of rat pulmonary arterial and aortal SMCs [1] as well as a number of
other cell types, including neural stem cells, pancreatic stellate cells,
murineﬁbroblasts, cancer cell linesMCF7, RKO,Hela, andHT1080 [2–4].
However, whether or not HPASMCs undergo similar cell proliferation in
response to hypoxia has not been determined. Therefore, we next
studied the effect of hypoxia on the cell proliferation of theHPASMCs by
measuring [3H] thymidine incorporation and counting the cell numbers.
[3H] thymidine incorporation (Fig. 5A) and the numbers of HPASMCs
(Fig. 5B) were markedly augmented to the same degree (by 90%) after
exposure to hypoxia, compared with the normoxia group. These data
demonstrate that, similar to pulmonary smoothmuscle cells from other
species [53–57], the HPASMCs undergo hypertrophic growth under the
stimulation of hypoxia.
We then determined the possible role of the SHH signaling pathway
in the cell proliferation of the HPASMCs in response to hypoxic
stimulation. The treatments with CyA and anti-SHH and anti-HIF
antibodies signiﬁcantly attenuated the hypoxia-induced [3H]-thymi-
dine incorporation and cell numbers of HPASMCs (Fig. 5A and B). In
contrast, the treatment with Tom, an inactive compound structurally-
related to CyA, did not produce clear inhibitory effects. The treatment
with CyA, anti-SHH and anti-HIF antibodies and Tom also did not alter
the [3H]-thymidine incorporation and cell numbers of HPASMCs under
the normal condition. [3H] Thymidine incorporation and the cell
numbers were also signiﬁcantly enhanced after stimulation with
growth factors which was partially inhibited by treatment with CyA,
but not Tom (Fig. 5A and B). These data demonstrate that hypoxia-
induced HPASMC proliferation is mediated at least in part by activating
the SHH pathway.
We sought to determine if the direct activation of the SHH pathway
could promote the cell proliferation of HPASMCs. Addition of the
recombinant human SHH into the culturemedium at a concentration of
1.0 μg/ml signiﬁcantly increased the cell proliferation of HPASMCs by
2.6-fold as measured by [3H]-thymidine incorporation (Fig. 5C).
Activation of the SHH pathway by incubation with Pur (4 μM) andSAG (100 nM), two SMO agonists, also signiﬁcantly augmented [3H]-
thymidine incorporation by 2.8- and 2.2-fold, respectively (Fig. 5C). The
increases in the [3H]-thymidine incorporation induced by SHH, Pur and
SAG were markedly reversed by CyA, but not Tom (Fig. 5C). These data
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signaling also provokes the cell proliferation of the HPASMCs.3.6. Enhancement of apoptosis by CyA in the hypoxic HPASMCs
We next examined the role of the SHH signaling pathway in the
apoptosis of the HPASMCs in response to hypoxia by ﬂow cytometry
after staining with the Annexin V- FITC (Annexin V) and propidium
iodide (PI). This method detects the cells in the necrotic (B1), late
apoptotic (B2), viable (B3), and early apoptotic states (B4) (Fig. 6A).
CyA treatment at a concentration of 20 μΜ did not clearly inﬂuence
the apoptosis of normoxia HPASMCs. In contrast, such a treatment
signiﬁcantly enhanced the number of annexin V-positive HPASMCs by
2.4-fold in the hypoxic condition compared with the treatment with
Tom (Fig. 6A and B). These results demonstrate that the SHH signalingHypoxia
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Fig. 6. Apoptosis induced by CyA in the HPASMCs. (A) Effect of CyA on the apoptosis of HP
(0.1%, Ctrl), CyA (5 μΜ) or Tom (5 μΜ) and then subjected to hypoxia. Apoptosis was meas
propidium iodide (PI). The lower left quadrants of each panel show the viable cells, which
represent the apoptotic cell, positive for AV binding and negative for PI uptake (B4, AV+/PI-)
with or without AV ﬂuorescence. X axis, ﬂuorescence height of AV; Y axis, ﬂuorescence heigh
such experiments were performed. (B) Quantitative data of the apoptotic cells in the B4 sect
with control (Ctrl) in the hypoxic group.pathway may be involved in the regulation of apoptosis in the
HPASMCs once subjected to hypoxia.
4. Discussion
The SHH signaling pathway is a well-known key mediator for many
fundamental processes in multiple organs during embryonic develop-
ment [58,59]. A recent study has demonstrated that the SHH signaling
components exist in the adult rat VSMCs and their expression can be
modulated by biomechanical stimulation both in vitro and in vivo,
suggesting that the SHH pathway may play a role in the arterial
remodeling and atherogenesis [60]. However, the role of the SHH
pathway in hypoxic pulmonary vascular remodeling has not been
studied. In this study, we used the adult HPASMCs as a cell model to
explore the possible function of the SHH activation in regulating cell
proliferation by hypoxia.Wehave demonstrated that hypoxiamarkedlyTom CyA
nnexin-V Annexin-V
*
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Hypoxia
ASMCs exposed to hypoxia. The HPASMCs were starved for 24 h, treated with ethanol
ured by ﬂow cytometry following staining with the Annexin V - FITC (Annexin V) and
exclude PI and are negative for AV binding (B3, AV-/PI-). The lower right quadrants
. The upper quadrants (left and right) represent the necrotic cells, positive for PI uptake
t of PI. Data was taken from one out of six determinations in a typical experiment. Three
ion presented as the means±S.E. of four independent experiments. ⁎Pb0.05 compared
1366 G. Wang et al. / Biochimica et Biophysica Acta 1803 (2010) 1359–1367activates the SHH pathway in the HPASMCs and that hypoxia also
enhances the proliferation of the HPASMCs which can be reversed by
inhibiting the SHH pathway.
We have demonstrated that the HPASMCs contain the main
components of the SHH pathway including SHH, SMO, PTCH1 and GLI.
More importantly, we have shown that hypoxia augmented SHH
expression and secretion into the culture medium. However, it is
interesting to note that the time courses of hypoxia-induced SHH
expression and secretion are clearly different. Although the maximal
expression of SHH was achieved at 8 h after hypoxia, maximal SHH
secretion into the culture mediumwas observed from 12 to 48 h after
hypoxia. One possible mechanism responsible for this discrepancy is
that the function of the proteins Dispatched (DISP), which have been
demonstrated to control the release of cholesterol-modiﬁed HH
[61,62], is altered by hypoxia. At 8 h after hypoxia, SHH secretion does
not reach the maximal level, which may be caused by the limited
expression/function of DISP. It is possible that hypoxia for a longer
period of time (e.g. N8 h) will stimulate the expression/function of
DISP, promoting the release of SHH into the culture medium.
Nevertheless, our data demonstrate that the expression of SHH in
the HPASMCs and its secretion into the culture medium are inducible
by hypoxia.
We have also shown that, under the normoxia condition, GLI1
mainly expresses in the cytoplasmic compartment and hypoxia
facilitates its translocation to the nuclei in the HPASMCs. The
subcellular localization of GLI1 as well as its nuclear translocation in
response to the activation of the SHH signaling pathway is still a
matter of debate. It has been demonstrated that the distribution of
GLI1 in the nuclei and the cytoplasmmay be different in different cells
and increasing evidence suggest that GLI1 subcellular localization is a
highly regulated process [63–66]. Increased GLI1 expression and
enhanced nuclear translocation [67] can be used an indicator for the
activation of the SHH pathway. Interestingly, it has been demonstrat-
ed that the expression of GLI1 is controlled by other GLI proteins
[68,69]. Taken together, our data demonstrate that the SHH pathway
is activated in the HPASMCs in response to hypoxia, reﬂected by
increased expression and secretion of SHH and the nuclear translo-
cation of GLI1. These data demonstrate for the ﬁrst time that hypoxia
is a strong stimulator for the SHH signaling pathway in the HPASMCs.
These data are also consistent withmany other reports demonstrating
that the SHH pathway can be activated by hypoxia in cardiomyoblast
cells, neurons, astrocytes, and neural progenitor cells [35,40–43].
The most exciting data presented in this manuscript is that cell
proliferation of the HPASMCs in response to hypoxia is mediated at
least in part through the SHH pathway. First, we have demonstrated
that hypoxia enhances cell proliferation of the HPASMCs as measured
by [3H]-thymidine incorporation and cell numbers. These results are
consistent with many other reports demonstrating that hypoxia is a
strong proliferation stimulator of pulmonary cells [70–73]. Second,
stimulation of the SHH pathway through addition of puriﬁed
recombinant SHH and administration of SMO agonists also promotes
cell proliferation. These results provide direct evidence implicating
that the SHH signaling pathway is involved in the regulation of
HPASMCs. Third, cell proliferation induced by hypoxia can be
inhibited by treatments with cyclopamine, a speciﬁc inhibitor of
SMO, and anti-SHH antibodies, further suggesting an important role of
the activation of SHH pathway in the hypoxia-mediated cell
proliferation in the HPASMCs. Future experiments will deﬁne the
role of SHH-PTCH-GLI pathway in the hypoxia-mediated HPASMC
growth in vivo.
Cyclopamine has been well shown to induce apoptosis in many
kinds of cancer cells, such as colorectal, pancreas, and small-cell lung
cancer [17,31,74]. Therefore, SHH antagonists are being developed for
the treatment of several cancers [75]. In addition, removal of the SHH
signaling from adult hearts results in cardiomyocyte apoptosis [76].
These suggest a protective role for the SHH signaling pathway. In thisreport, we have demonstrated that administration of cyclopamine to
inhibit the SHH pathway strongly enhanced apoptosis in the
HPASMCs speciﬁcally under the hypoxia condition. As hypoxia
activates the SHH pathway, these data suggest that activation of the
SHH is involved in the regulation of apoptosis of the hypoxic
HPASMCs. These results provide important evidence implying that
the SHH antagonists may be used as therapeutic agents for hypoxia-
induced diseases.
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